Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Not Recruiting

Trial ID: NCT04911478


The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

Official Title

Long-term Follow-up Protocol for Subjects Treated With Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products

Stanford Investigator(s)

David Miklos
David Miklos

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)


Inclusion Criteria:

   - All patients who received any Adicet allogeneic CAR T investigational product and have
   either completed the core treatment protocol or have discontinued early

   - All patients who are willing and able to adhere to the study visit schedule and other
   protocol requirements.

   - Capable of giving signed informed consent which includes compliance with requirements
   and restrictions listed in the informed consent form (ICF) and protocol

Exclusion Criteria:

   - There are no specific exclusion criteria for this study


genetic: ADI-001

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Miklos, MD